Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2 by Kalalinia, F. et al.
Asian Pacific Journal of Cancer Prevention, Vol 13, 2012 2979
     DOI:http://dx.doi.org/10.7314/APJCP.2012.13.6.2979 
TPA Modulates Chemoresistance in MCF-7 Cells through the ABCG2 Drug Efflux Transporter
Asian Pacific J Cancer Prev, 13, 2979-2984
Introduction
 In cancer treatment, prolonged chemotherapy could 
lead to the selective survival of multidrug resistant 
(MDR) cells that exhibit simultaneous resistance to a 
wide spectrum of structurally and functionally unrelated 
chemotherapeutic agents. One of the mechanisms leading 
to MDR is the over-expression of membrane efflux protein 
breast cancer resistance protein (BCRP). 
 The 72 kDa breast cancer resistance protein (BCRP) is 
the second member of the subfamily G of the human ATP 
binding cassette (ABC) transporter superfamily, designated 
as ABCG2 (Mao & Unadkat, 2005). ABCG2 is present 
in normal tissues, such as placental syncytiotrophoblasts, 
pancreas, small intestine, colon, hepatocytes, breast and 
in venous and capillary endothelial cells of almost all 
tissues (Maliepaard et al., 2001; Doyle & Ross, 2003). 
The functional characteristics and the distribution of 
ABCG2 suggest that this transporter protects the organism 
from many potentially harmful xenobiotics by decreasing 
intracellular concentration of them (Doyle & Ross, 2003; 
Huls et al., 2009). Overexpression of ABCG2 is associated 
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Abstract
 Recent studies have indicated a link between levels of cyclooxygenase-2 (COX-2) and development of the 
multidrug resistance (MDR) phenotype. The ATP-binding cassette sub-family G member 2 (ABCG2) is a major 
MDR-related transporter protein that is frequently overexpressed in cancer patients. In this study, we aimed 
to evaluate any positive correlation between COX-2 and ABCG2 gene expression using the COX-2 inducer 
12-O-tetradecanoylphorbol-13-acetate (TPA) in human breast cancer cell lines. ABCG2 mRNA and protein 
expression was studied using real-time RT-PCR and flow cytometry, respectively. A significant increase of 
COX-2 mRNA expression (up to 11-fold by 4 h) was induced by TPA in MDA-MB-231 cells, this induction effect 
being lower in MCF-7 cells. TPA caused a considerable increase up to 9-fold in ABCG2 mRNA expression in 
parental MCF-7 cells, while it caused a small enhancement in ABCG2 expression up to 67 % by 4 h followed 
by a time-dependent decrease in ABCG2 mRNA expression in MDA-MB-231 cells. TPA treatment resulted 
in a slight increase of ABCG2 protein expression in MCF-7 cells, while a time-dependent decrease in ABCG2 
protein expression was occurred in MDA-MB-231 cells. In conclusion, based on the observed effects of TPA in 
MDA-Mb-231 cells, it is proposed that TPA up-regulates ABCG2 expression in the drug sensitive MCF-7 breast 
cancer cell line through COX-2 unrelated pathways. 
Keywords: ATP-binding cassette transporter - ABCG2 - breast cancer cell lines - cyclooxygenase-2 
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with high levels of resistance to a variety of anticancer 
agents. ABCG2 expression has been detected in a large 
number of hematological malignancies and solid tumors, 
indicating that this transporter may play an important role 
in clinical drug resistance of cancers (Ross et al., 2000; 
Diestra et al., 2002). 
 In recent years, there have been increasing 
interest in examining several factors such as COX-
2 (Cyclooxygenase-2) causing multidrug resistance 
via increased the expression of MDR transporters 
proteins. Cyclooxygenases, also known as prostaglandin 
endoperoxide synthases or prostaglandin H synthases, 
comprises a group of enzymes that participate in the 
conversion of arachidonic acid to prostaglandins that affect 
a number of physiological and pathological states (Smith & 
Dewitt, 1996). The expression of the two COX isoenzymes 
is differently regulated. Constitutively expressed COX-1 
supplies normal tissues with prostaglandins required to 
maintain physiological organ functions (O’Neill & Ford-
Hutchinson, 1993), such as cytoprotection of the gastric 
mucosa (Chan et al., 1995) and regulation of renal blood 
flow (Tanioka et al., 2003). On the other hand, COX-2 is 
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highly induced by inflammatory signals, growth factors 
and cytokines at sites of inflammation (Smith & Dewitt, 
1996; Dubois et al., 1998). Therefore, it is assumed that 
COX-2 plays an important role in the prostaglandin 
E2 (PGE2) production involved in pathophysiological 
processes (Trebino et al., 2003). COX-2 may be implicated 
in tumor promotion through modulating cell proliferation, 
inhibiting apoptosis, control of cell migration, cell 
adhesion, tumor invasion and suppression of immune 
response (Cao & Prescott, 2002). In recent years, it has 
been reported that COX-2 modulates ABC transporter 
expression and is involved in the development of the MDR 
phenotype. A correlation between expression of COX-2 
and MDR1 was found in breast cancer (Ratnasinghe et al., 
2001), hepatocellular carcinoma (Fantappiè & R, 2002 ), 
and acute myeloblastic lymphoma (Puhlmann et al., 2005). 
Previously, we demonstrated that induction of COX-2 
expression could increase ABCG2 activity (mitoxantrone 
efflux) in breast cancer cell lines (Kalalinia et al., 2010). 
 In the present study, we addressed the question as 
to whether a regulative link exists between the COX-2 
expression and the mRNA and protein expression of 
ABCG2 transporter in breast cancer cell lines. Our results 
suggest that COX-2 inducer TPA up-regulate ABCG2 
expression which looks like to happen with a COX-2-
independent mechanism.
 
Materials and Methods
Reagents and Antibodies 
 Antibody to human COX-2 was obtained from 
Cayman Chemical Company (Ann Arbor, MI, USA). 
BCRP/ABCG2 antibody (BXP-21) was obtained from 
Abcam (Cambridge, UK). TPA, bovine serum albumin 
(BSA), penicillin–streptomycin were purchased from 
Sigma–Aldrich (Germany). RPMI 1640 with L-glutamine 
and FBS were purchased from Biosera (UK) and Gibco 
(USA), respectively.
Cell culture and treatments
 We used the human breast carcinoma cell lines. MCF-7 
and its ABCG2-overexpressing, mitoxantrone-resistance 
derivative, MCF7/MX cell lines was generously provided 
by Dr. Erasmus Schneider (Wadsworth Center, New York 
State Department of Health, USA) and MDA-MB-231 
cells was generously provided by Dr. Mohammad Kazem 
Koohi (Faculty of Veterinary Medicine, university of 
Tehran, Iran). MDA-MB-231 cells were chosen as a 
control cell line because they are known to express COX-
2. Cells were cultured in RPMI 1640 supplemented with 
fetal bovine serum (FBS) 10% (w/v), penicillin (50,000 
units/L), and streptomycin (50 mg/L) at 37 °C in the 
presence of CO2 5%. MX-resistant cells were grown in the 
medium containing mitoxantrone at a 10−7 M concentration 
to maintain the multidrug-resistant phenotype. MCF7/MX 
cells were cultured on MX free medium for at least 7 days 
prior to experiments. Since FBS has been shown to induce 
COX-2 (due to the presence of growth factors) (Shen et 
al., 2004), subconfluent cells were washed and changed 
to serum-free medium containing BSA 0.1% (w/v) for 
24 h before treatment. For real-time PCR studies, the 
breast cancer cells were incubated for 4-48 h with TPA 
(0–100 nM). For flow-cytometry analysis, all cell lines 
were treated with TPA 10 nM for 4, 24 and 48 h. After 
specific treatments, cells were trypsinized and harvested 
for isolation of total RNA or used for protein expression 
studies by flow cytometry.
RNA Extraction and Reverse Transcription-Real-Time 
Polymerase Chain Reaction (RT-PCR)
 In order to evaluate ABCG2 and COX-2 expression 
in breast cancer cell lines under TPA treatment, real-time 
RT-PCR analysis was performed. Total RNA was isolated 
from subconfluent treated cells (with TPA 0-100 nM for 
4-48 h) using High Pure RNA Isolation Kit from Roche 
Applied Science according to the protocol provided 
by the manufacturer. To prevent DNA contamination, 
RNA was treated with ribonuclease-free DNase (which 
supplied with RNA Isolation Kit). The total amount 
of extracted RNA was quantified using a NanoDrop 
1000 spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE).The purity of the RNA samples were 
determined by the ratio of absorbance at 260 nm and 
280 nm and the ratio of absorbance at 260 nm and 230 
nm, acceptable ratios were in the range of 1.8-2.2. One 
step real-time RT-PCR was performed on the RNA 
samples using EXPRESS One-Step SYBR® GreenER™ 
Universal kit (Invitrogen) and Stratagene 3000 p 
sequence detector system. The sequences of primer pairs 
(TAG Copenhagen A/S, Denmark) were: ABCG2: 5´- 
TATCAATGGGATCATGAAACCTGG-3´ (forward) and 
5´-GCGGTGCTCCATTTATCAGAAC-3´(reverse); COX-
2, 5´-AATCATTCACCAGGCAAATTG- 3´ (forward ) and 
5´-TCTGTACTGCGGGTGGAACA- 3´ (reverse ); β-actin: 
5´-TCATGAAGTGTGACGTGGACATC-3´ (forward) 
and 5´-CAGGAGGAGCAATGATCTTGATCT-3´ 
(reverse) (Rapisarda et al., 2002; Lin et al., 2003; Buchholz 
et al., 2006). Reactions were performed with an initial 
step at 57 °C for 5 min (cDNA synthesis), followed by a 
denaturation step at 95 °C for 2 min, 40 cycles at 95 °C 
for 15 s, 60 °C for 1 min. Amplification of a single product 
for each primer set was confirmed by the dissociation 
curve analysis. Standard curves were prepared for target 
(ABCG2 and COX-2) and reference (β-actin) genes. 
Relative expression levels for each gene of interest were 
normalized to that of the β-actin by the MxPro-Mx3000P 
system. The results were expressed as the target/reference 
ratio of the treated samples divided by the target/reference 
ratio of the untreated control sample.
Intracellular staining of COX-2 
 The COX-2 protein expression of the breast cancer 
cell lines under treatment with TPA 10 nM for 4, 24 and 
48 h was measured by flow cytometric assay which was 
developed for internal detection of COX-2 in fixed and 
permeabilized cells. Briefly, 1 ×106 cells were washed with 
BSA 2% (w/v) in PBS. The cells were fixed by adding 
Leucoperm reagent A (fixation medium) and incubated for 
15 min at RT (Room Temperature). Following washing 
with PBS which contained Tween 0.01% (w/v) (PBST), 
the cells were permeabilized by resuspending with 
Leucoperm reagent B (Permeabilization Medium) and 
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incubated at RT for 15 min. After washing and blocking 
the cells with BSA 10% (w/v), cells were incubated for 30 
min at RT with 50 ng of phycoerythrin (PE) - conjugated 
anti-COX-2 mAbs. The cells were washed with PBST 
and resuspended in sheath fluid for immediate analysis 
or in formaldehyde 0.5% and stored at 2-8oC in the dark 
for later analysis within 24 hours.
Indirect staining of ABCG2 
 To study the effect of COX-2 induction by TPA on 
the expression of ABCG2, Flow cytometry detection 
of ABCG2 expression in control and treated cells was 
performed using the method described by Minderman et 
al. (Minderman et al., 2002) with slight modifications. 
Cells were washed with PBS and fixed in formaldehyde 
3.7% (w/w) for 10 min at room temperature, then in ice-
cold methanol 90% (v/v) for 10 min. Thereafter, cells were 
washed with PBST and blocked with BSA 10% (w/v) for 
1 h at room temperature. Cells were then incubated for 
60 min on ice with primary monoclonal antibody BXP-
21 (1:100 in BSA 2% (w/v)), which recognizes internal 
epitopes of the ABCG2 protein (Maliepaard et al., 2001). 
After washing with PBST, Cells were incubated for 20 
min on ice and protected from light with a Fluorescein 
isothiocyanate (FITC)-conjugated goat anti-mouse 
antibody with a final dilution 1:50 in PBST to detect the 
primary anti-ABCG2 mAb. After the final wash with 
PBST, cells were resuspended in PBS with BSA 2% (w/v) 
and stored on ice in the dark prior to analysis.
Flow cytometric detection of COX-2 and ABCG2 
expression
 Samples were analyzed on a PartecTM cytometer 
equipped with a standard argon laser 488-nm excitation, 
and with 530/30 band pass filter for FL1 and a 585/42 
band pass filter for FL2 for detection of FITC and PE 
fluorescence, respectively. To exclude cell debris and 
clumps, samples were gated on forward scatter versus 
side scatter. Fluorescence of 10,000 cells was quantified 
from histogram plots using the mean fluorescence intensity 
(MFI). Flow cytometry data were processed and analyzed 
using FloMax version 2.52 and WinMdi version 2.9 
software. Fold change was calculated by dividing the MFI 
of the treated sample (MFI treated) by that of the untreated 
sample (MFI untreated).
Statistical analysis
 All experiments were performed in duplicate or 
triplicate on three independent occasions. Statistically 
significant differences between values were determined 
using multivariate analysis of variance (MANOVA) 
with Tukey’s post-hoc. All the data are expressed as 
mean±S.D., and P<0.05 was considered to be statistically 
significant.
Results 
 The first objective was to confirm the induction of 
the COX-2 expression in MCF-7, MCF7/MX and MDA-
MB-231 cells with TPA. Figure 1 indicates that TPA can 
stimulate the expression of COX-2 within MDA-MB-231 
Figure 1. Time Course Study of the Effects of TPA 
on COX-2 mRNA Expression in MDA-MB-231 Cells. 
Cells were treated with TPA (0-100 nM for 4-48 h) and real-time 
RT-PCR analysis was performed on total RNA extracted from 
control and treated cells. Values were normalized to the β-actin 
content of samples. The results were expressed as the target/
reference ratio of the treated samples divided by the target/
reference ratio of the untreated control sample and expressed as 
mean±SD (n=3); *, p<0.05; **, p<0.01; ***, p<0.001
cells. This induction effect of the TPA on the expression of 
COX-2 was concentration-dependent and decreased as the 
incubation time of this cell line increased. The basal levels 
of COX-2 mRNA expression were increased more than 
11-fold in 4 h and it was negligible 48 h after treatment.  
The most induction effect of TPA on the expression of 
COX-2 was observed with TPA 10 nM by 12 h and TPA 
20 nM by 24 h in MCF-7 and MCF7-MX, respectively.
 The differential COX-2 protein expression as a result 
of COX-2 mRNA overexpression with TPA 10 nM was 
also evaluated by flow cytometry. As shown in Figure 2, 
COX-2 protein was up-regulated in MCF-7 (4-48 h) and 
MDA-MB-231(4 h), as a difference of more than 60% was 
considered significant in MCF-7 cells. On the other hand, 
COX-2 protein expression was slightly reduced (about 15 
% vs. control) under TPA treatment in MCF7/MX cells.
 The relationship between induction of COX-2 
expression and expression of ABCG2 was studied using 
real-time RT-PCR. Breast cancer cells were treated with 
TPA 0-100 nM for 4-48 h. Figure 3 shows the results 
of these preliminary experiments. We observed a slight 
Figure 2. COX-2 Protein Expression in MCF-7, MCF7/
MX and MDA-MB-231 Cell Lines. Cells were treated with 
TPA (10 nM for 4, 24 and 48 h) and COX-2 protein expression 
was measured by flow cytometric assay which developed for 
internal detection of COX-2. Briefly, cells were fixed and 
permeabilized by Leucoperm (fixation and permeabilization 
medium) and blocked with BSA. Then, they were incubated 
with PE- conjugated anti-COX-2 mAbs for 30 min at RT. COX-
2 protein level expressed as ratio of: MFItreated sample /MFI untreated 
sample The values are shown as mean±S.D. (n=3); *, p <0.05; **, 
p <0.01; ***, p <0.001”.
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Figure 4. Expression of ABCG2 Protein in Wild 
Type and Resistant Cell Lines was Studied by Flow 
Cytometry with the BXP-21 Monoclonal Antibody. 
Cells were fixed and permeabilized by formaldehyde 3.7% (w/w) 
and methanol 90% (v/v). Thereafter, cells were blocked with 
BSA 10% (w/v) and then incubated with primary monoclonal 
antibody BXP-21. After washing, Cells were incubated with 
a FITC-conjugated goat anti-mouse antibody. Fluorescence 
of 10,000 cells was quantified from histogram plots using the 
FITC fluorescence. 
Figure 5. Effect of TPA on ABCG2 Protein Levels in A, MCF-7, B, MCF-7-MX and C, MDA-MB-231 Cells. 
After 48-h incubation with TPA (10 nM), expression of ABCG2 protein was measured by flow cytometry. Each histogram shows 
the overlay of the treated sample (dark gray), untreated sample (black) and secondary antibody as negative control (light gray).
increase in ABCG2 expression in resistance cell line 
MCF7/MX (Figure 3A), while a considerable increase 
up to 9-fold in ABCG2 expression was observed in the 
parental MCF-7 cells (Figure 3B). On the other hand, 
interesting results were observed in MDA-MB-231 
(Figure 3C), whereas small enhancement in ABCG2 
expression up to 67 % was observed in 4 h while increasing 
the incubation time reverse this process and showed 
a time-dependent decrease to about 85 % in ABCG2 
expression. 
Figure 3. Effects of TPA on the Levels of ABCG2 mRNA in A, MCF-7-MX, B, MCF-7, and C, MDA-MB-231 
Cell Lines. Cells were treated with TPA (0-100 nM for 4-48 h) and ABCG2 mRNA expression was measured by real-time RT-PCR 
using total RNA extracted from control and treated cells. Relative expression levels for each gene were normalized to that of the 
β-actin. The results were expressed as: (target/reference ratio)treated samples/(target/reference ratio)untreated control sampl. Values were expressed 
as mean±SD (n=3); *, p<0.05; **, p<0.01; ***, p<0.001”.
         A    B             C
 It was necessary to investigate whether the increased 
gene expression was associated with increased translation 
of the protein. All cell lines were treated with TPA (10 
nM for 4, 24 and 48 h), and ABCG2 protein expression 
were analyzed by flow cytometry. At basal level (without 
treatment), higher FITC fluorescence of MCF-7/MX 
histogram was observed in compared to FITC fluorescence 
of MCF-7 and MDA-MB231 histogram which confirmed 
the overexpression of ABCG2 protein in MCF7/MX cells 
(Figure 4). The results showed a slight increase of ABCG2 
expression in MCF-7 with the highest effect at 48 h (Figure 
5A), while no significant changes in the level of ABCG2 
expression was observed in MCF7/MX (Figure 5B). On 
the contrary, treatment of MDA-MB-231 cells with TPA 
resulted in a time-dependent decrease in ABCG2 protein 
expression wherever the maximum intensity (about 10 %) 
was seen at 48 hours (Figure 5C). Using flow cytometry 
analysis we were able to confirm the real-time PCR results.
 
Discussion
Multidrug resistance may be one of the major reasons 
for the failure of chemotherapy in human cancers. Energy 
dependent drug efflux involving ABCG2 is believed to 
result in reduced drug accumulation and sensitivity to 
a variety of natural products used in the treatment of 
cancers. We have previously showed that proinflammatory 
cytokines IL-1β and TNF-α induced ABCG2 and 
pregnane X receptor (PXR) expression in breast cancer 
cell line MCF-7 (Mosaffa et al., 2009; Malekshah et 
al., 2011). In another study, it has been indicated that 
dexamethasone (an anti-inflammatory drug) reduced the 
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expression of ABCG2 mRNA in MCF-7 and MCF-7/
MX breast cancer cell lines. In addition, the level of 
ABCG2 protein expression and function was decreased 
in dexamethasone-treated MCF-7/MX cells (Elahian et 
al., 2009: 2010). During the last decade, numerous studies 
have reported that enforced expression of COX-2 causes 
enhancement of multidrug resistance proteins expression 
in different cancer cell lines (Patel et al., 2002; Sorokin, 
2004; Surowiak et al., 2005; 2006; 2008; Lee et al., 2007;). 
In the present study, we aimed to evaluate the existence 
of a positive correlation between COX-2 and ABCG2 
gene expression using COX-2 inducer TPA in three breast 
cancer cell lines. 
The results indicated that TPA could induce COX-2 
expression in all tested cell lines. Our report is consistent 
with of Liu et al. who showed that in contrast to MCF-7 
cells, the biologically aggressive, invasive MDA-MB-23l 
cell line possesses a high constitutive level of COX-2 
mRNA and also displays a further and prolonged increase 
in the expression of the COX-2 protein in response to TPA 
(Liu and Rose, 1996). Furthermore, the amount of COX-2 
mRNA induction and production of COX-2 protein were 
closely related in MCF-7 and MCF7/MX cells. 
In the MDA-MB-231 cell line, real-time RT-PCR 
revealed a 6-fold increase in COX-2 mRNA in response 
to TPA 10 nM but only a 60% increase in the protein 
level was shown by flow cytometry. These results are in 
agreement with the reports by liu et al. (Liu & Rose, 1996), 
Lee et al. (Lee et al., 1992) and Kargman et al. (Kargman et 
al., 1995) that high COX-2 mRNA expression may occur 
in human breast cancer cells and colorectal adenomas 
without a associated increase in COX-2 protein. It seemed 
that COX-2 may go through complex posttranscriptional 
and posttranslational modification to yield the active 
enzyme.
In MCF-7 cells, TPA treatment increased ABCG2 
expression up to 9-fold. While, TPA treatment could not 
significantly stimulate ABCG2 expression in MCF7-MX. 
In the drug resistant MCF7/MX cells, ABCG2 is already 
overexpressed, and its expression may be at a threshold 
maximum level. Perhaps an induction with TPA treatment 
may not be causing any detectable increase in mRNA level 
(Elahian et al., 2009; Mosaffa et al., 2009). 
We previously reported that TPA enhanced ABCG2 
activity in breast cancer cell lines (Kalalinia et al., 2010). 
In the present study, we showed that TPA increases 
the ABCG2 expression in MCF-7 cell line while it 
significantly decreased ABCG2 expression in MDA-
MB-231 cells. Considering what was mentioned earlier, 
TPA increased COX-2 expression several fold to control 
level in MDA-MB-231 cell which was significantly 
greater than the effect observed in other tested cell lines. 
So overall it seems that the observed effect of TPA on 
ABCG2 expression may be COX-2 independent. Different 
studies showed that incubation of MDR cells with protein 
kinase C (PKC) activator TPA stimulate P-glycoprotein 
(P-gp) phosphorylation, reduce drug accumulation, and 
enhance drug resistance (Ramachandran et al., 1998). 
Fine et al. demonstrated that 12,13-dibutyrate [P(BtO)2] 
led to an increase in protein kinase C activity and induced 
a drug-resistance phenotype as a result of increased 
phosphorylation of an unknown 20-kDa particulate 
protein (Fine et al., 1988). Similar to TPA treatment, 
Diacylglycerol (DAG), a physiological stimulant of 
PKC, also increased the expression of MDR1 mRNA and 
protein. Whereas, protein kinase inhibitor staurosporine 
suppressed the induction of MDR1 expression by TPA 
and DAG (Chaudhary and Roninson, 1992). These reports 
suggest that MDR1 gene expression in different cell types 
is regulated by a PKC-mediated pathway. In addition, 
TPA induces several biological cellular procedures such 
as differentiation and causes reduced drug influx (Drew 
et al., 1996). On the other hand, Drew et al. proposed a 
P-gp independent drug resistance due to a PKC-mediated 
process, which is maintained after depletion of certain 
PKC subspecies or is due to activation of down regulation 
insensitive PKC subspecies (Drew et al., 1996). To our 
knowledge, there are no similar reports about ABCG2; 
further studies are needed to determine whether TPA 
induces PKC, COX-2 or any of the above-mentioned 
cellular events resulting in increased ABCG2 expression 
and function.
In conclusion, we found that TPA stimulate COX-2 
mRNA expression up to 11-fold in MDA-MB-231 while 
it caused a slight induction of COX-2 expression in 
MCF-7 and MCF7/MX cell lines. TPA caused ABCG2 
overexpression in drug sensitive and drug resistant MCF-
7 cell lines, while it reduced the ABCG2 expression in 
MDA-MB-231 cells. Therefore, the existence of a positive 
correlation between COX-2 and ABCG2 gene expression 
remains to be questioned according to observed effects of 
the COX-2 inducer TPA in MDA-MB-231 cells. Further 
studies should be performed on COX-2 pathway to 
more clarify the observed effects. The discovery of this 
relationship will facilitate the development of strategies 
to fight multidrug resistance in tumors which overexpress 
the COX-2 protein.
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